Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$11.2B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing novel therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of a company's profitability, and investors will be watching closely to see if Axsome can narrow its losses.

$-0.84

Revenue

Revenue figures will provide insight into the company's sales performance and market acceptance of its products.

$222M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing novel therapies for central nervous system disorders. With a market cap of $11 billion, its work is particularly relevant as mental health and neurological conditions gain increasing attention in healthcare.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1-2026, Axsome reported an EPS of $-1.26, which was a significant miss compared to the estimate of $-0.85. Despite the disappointing earnings, the stock rose by 8.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Axsome to report a loss but are looking for signs of improving revenue. The market is divided on whether the company can meet or exceed these expectations.

Bull Case

If Axsome can show a smaller loss than expected and strong revenue growth, it could signal that its products are gaining traction in the market.

Bear Case

Conversely, if the company reports a larger loss and lower revenue, it may raise concerns about its product pipeline and market strategy.

Key Metrics to Watch

EPS

$-0.84

Earnings per share (EPS) is a key indicator of a company's profitability, and investors will be watching closely to see if Axsome can narrow its losses.

Revenue

$222M

Revenue figures will provide insight into the company's sales performance and market acceptance of its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's EPS come in better than the consensus estimate of $-0.84?

A smaller loss could indicate improving operational efficiency and market demand for its products.

What revenue figures will Axsome report, and how do they compare to the consensus of $222 million?

Revenue performance will be crucial in assessing the company's growth trajectory and market acceptance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Axsome's potential for revenue growth due to the recent focus on mental health treatments, which could lead to stronger-than-expected sales.

Supporting Evidence

The options market is pricing in a 19.2% move, indicating expectations of significant volatility that may not align with historical performance.

Axsome's recent product developments may not be fully reflected in analyst estimates, suggesting potential upside.

Key Risk

If revenue exceeds $258 million, it could challenge the current bearish sentiment and validate the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining Axsome's ability to recover from previous misses and establish a stronger market presence.

Bull Confirmed If

An EPS loss of less than $-0.84 combined with revenue exceeding $222 million would confirm a bullish outlook.

Bear Confirmed If

An EPS loss greater than $-1.25 and revenue below $200 million would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by around 2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, the average reaction has been a decline of about 1.28%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected market impact.
2Details on sales performance and customer feedback for existing products.
3Management's outlook on future revenue growth and market conditions.
4Insights into operational efficiencies and cost management strategies.
5Responses to competitive pressures in the pharmaceutical sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing novel therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of a company's profitability, and investors will be watching closely to see if Axsome can narrow its losses.

$-0.84

Revenue

Revenue figures will provide insight into the company's sales performance and market acceptance of its products.

$222M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1-2026, Axsome reported an EPS of $-1.26, which was a significant miss compared to the estimate of $-0.85. Despite the disappointing earnings, the stock rose by 8.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Axsome to report a loss but are looking for signs of improving revenue. The market is divided on whether the company can meet or exceed these expectations.

Bull Case

If Axsome can show a smaller loss than expected and strong revenue growth, it could signal that its products are gaining traction in the market.

Bear Case

Conversely, if the company reports a larger loss and lower revenue, it may raise concerns about its product pipeline and market strategy.

Key Metrics to Watch

EPS

$-0.84

Earnings per share (EPS) is a key indicator of a company's profitability, and investors will be watching closely to see if Axsome can narrow its losses.

Revenue

$222M

Revenue figures will provide insight into the company's sales performance and market acceptance of its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's EPS come in better than the consensus estimate of $-0.84?

A smaller loss could indicate improving operational efficiency and market demand for its products.

What revenue figures will Axsome report, and how do they compare to the consensus of $222 million?

Revenue performance will be crucial in assessing the company's growth trajectory and market acceptance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Axsome's potential for revenue growth due to the recent focus on mental health treatments, which could lead to stronger-than-expected sales.

Supporting Evidence

The options market is pricing in a 19.2% move, indicating expectations of significant volatility that may not align with historical performance.

Axsome's recent product developments may not be fully reflected in analyst estimates, suggesting potential upside.

Key Risk

If revenue exceeds $258 million, it could challenge the current bearish sentiment and validate the company's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining Axsome's ability to recover from previous misses and establish a stronger market presence.

Bull Confirmed If

An EPS loss of less than $-0.84 combined with revenue exceeding $222 million would confirm a bullish outlook.

Bear Confirmed If

An EPS loss greater than $-1.25 and revenue below $200 million would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by around 2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, the average reaction has been a decline of about 1.28%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected market impact.
2Details on sales performance and customer feedback for existing products.
3Management's outlook on future revenue growth and market conditions.
4Insights into operational efficiencies and cost management strategies.
5Responses to competitive pressures in the pharmaceutical sector.